| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ashini Singh, Suman Sinha, Niraj Kumar Sing. Dietary Natural Flavonoids: Intervention for MAO-B Against Parkinson's Disease. Chemical biology & drug design. vol 104. issue 3. 2024-09-03. PMID:39223743. |
the precise etiology of pd remains elusive, but recent research has shed light on potential factors, including the formation of α-synuclein aggregates, oxidative stress, neurotransmitter imbalances, and dopaminergic neurodegeneration in the substantia nigra pars compacta (snpc) region of the brain, culminating in motor symptoms such as bradykinesia, akinesia, tremors, and rigidity. |
2024-09-03 |
2024-09-05 |
Not clear |
| Tania Arora, Gaurav Sharma, Vikash Prashar, Randeep Singh, Arti Sharma, Harish Changotra, Jyoti Parkas. Mechanistic Evaluation of miRNAs and Their Targeted Genes in the Pathogenesis and Therapeutics of Parkinson's Disease. Molecular neurobiology. 2024-06-01. PMID:38823001. |
pd is mainly caused by the demolition of the primary dopamine neurotransmitter secretory cells and dopaminergic or dopamine secretory neurons in the substantia nigra pars compacta of the midbrain, which are majorly responsible for motor functions. |
2024-06-01 |
2024-06-03 |
Not clear |
| Sen-Miao Li, Dian-Dian Wang, Dan-Hua Liu, Xiao-Yan Meng, Zhizhong Wang, Xitong Guo, Qian Liu, Pei-Pei Liu, Shu-Ang Li, Songwei Wang, Run-Zhou Yang, Yuming Xu, Longde Wang, Jian-Sheng Kan. Neurotransmitter accumulation and Parkinson's disease-like phenotype caused by anion channelrhodopsin opto-controlled astrocytic mitochondrial depolarization in substantia nigra pars compacta. MedComm. vol 5. issue 6. 2024-05-18. PMID:38756440. |
neurotransmitter accumulation and parkinson's disease-like phenotype caused by anion channelrhodopsin opto-controlled astrocytic mitochondrial depolarization in substantia nigra pars compacta. |
2024-05-18 |
2024-05-27 |
Not clear |
| Jillian L Seiler, Xiaowen Zhuang, Alexandra B Nelson, Talia N Lerne. Dopamine across timescales and cell types: Relevance for phenotypes in Parkinson's disease progression. Experimental neurology. 2024-01-19. PMID:38242300. |
dopamine neurons in the substantia nigra pars compacta (snc) synthesize and release dopamine, a critical neurotransmitter for movement and learning. |
2024-01-19 |
2024-01-22 |
Not clear |
| Jie Zhang, Jia Li, Cheng-Xi Liu, Huan Gui, Cheng-Dong Yuan, Yi Zhan. The role of intracerebral dopamine D1 and D2 receptors in sleep-wake cycles and general anesthesia. Ibrain. vol 8. issue 1. 2023-10-03. PMID:37786416. |
dopamine (da), a monoamine neurotransmitter, is synthesized and released mainly by neurons in the ventral tegmental area and the substantia nigra (sn) pars compacta of the midbrain. |
2023-10-03 |
2023-10-07 |
Not clear |
| Kamil Pradel, Gniewosz Drwięga, Lukasz Chrobok, Tomasz Błasia. Racing and Pacing in the Reward System: A Multi-Clock Circadian Control Over Dopaminergic Signalling. Frontiers in physiology. vol 13. 2022-07-11. PMID:35812323. |
while endogenous circadian rhythms are weak in the ventral tegmental area and substantia nigra pars compacta, daily changes in expression of core clock genes, ion channels, neurotransmitter receptors, dopamine-synthesising enzymes, and dopamine transporters, accompanied by changes in electrical activity, are readily observed in these nuclei. |
2022-07-11 |
2023-08-14 |
human |
| Muhammed Khairujjaman Mazumder, Anupom Borah, Shuvasish Choudhur. Inhibitory potential of plant secondary metabolites on anti-Parkinsonian drug targets: Relevance to pathophysiology, and motor and non-motor behavioural abnormalities. Medical hypotheses. vol 137. 2021-05-14. PMID:31954292. |
parkinson's disease (pd), a progressive neurodegenerative motor disorder, is caused due to the loss of dopaminergic neurons in the substantia nigra pars compacta region of mid-brain and the resultant depletion of the levels of the neurotransmitter dopamine. |
2021-05-14 |
2023-08-13 |
Not clear |
| T Mann, K Zilles, H Dikow, A Hellfritsch, M Cremer, M Piel, F Rösch, A Hawlitschka, O Schmitt, A Wre. Dopamine, Noradrenaline and Serotonin Receptor Densities in the Striatum of Hemiparkinsonian Rats following Botulinum Neurotoxin-A Injection. Neuroscience. vol 374. 2018-11-20. PMID:29421436. |
parkinson's disease (pd) is characterized by a degeneration of dopaminergic neurons in the substantia nigra pars compacta (snpc) that causes a dopamine (da) deficit in the caudate-putamen (cpu) accompanied by compensatory changes in other neurotransmitter systems. |
2018-11-20 |
2023-08-13 |
rat |
| Jasem Estakhr, Danya Abazari, Kaitlyn Frisby, J Michael McIntosh, Raad Nashm. Differential Control of Dopaminergic Excitability and Locomotion by Cholinergic Inputs in Mouse Substantia Nigra. Current biology : CB. vol 27. issue 13. 2018-07-31. PMID:28648825. |
understanding how dopaminergic (da) neurons of the substantia nigra pars compacta (snc) govern movements requires a detailed knowledge of how different neurotransmitter systems modulate da neuronal excitability. |
2018-07-31 |
2023-08-13 |
mouse |
| Tim D Auman. Environment- and activity-dependent dopamine neurotransmitter plasticity in the adult substantia nigra. Journal of chemical neuroanatomy. vol 73. 2016-09-06. PMID:26718607. |
in this chapter i consolidate recent evidence from my laboratory suggesting neurons in the adult mouse substantia nigra pars compacta (snc) also undergo da neurotransmitter plasticity in response to persistent changes in their electrical activity, including that driven by the mouse's environment or behavior. |
2016-09-06 |
2023-08-13 |
mouse |
| Justine Renaud, Seyed Fazel Nabavi, Maria Daglia, Seyed Mohammad Nabavi, Maria-Grazia Martinol. Epigallocatechin-3-Gallate, a Promising Molecule for Parkinson's Disease? Rejuvenation research. vol 18. issue 3. 2016-03-15. PMID:25625827. |
parkinson's disease (pd) is the second most common neurodegenerative disease, and it is characterized by the loss of the neurotransmitter dopamine and neuronal degeneration in the substantia nigra pars compacta. |
2016-03-15 |
2023-08-13 |
human |
| Chandana Buddhala, Susan K Loftin, Brandon M Kuley, Nigel J Cairns, Meghan C Campbell, Joel S Perlmutter, Paul T Kotzbaue. Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease. Annals of clinical and translational neurology. vol 2. issue 10. 2015-10-19. PMID:26478895. |
therefore, we quantified regional deficits in innervation from these pd-affected subcortical nuclei, by measuring the neurotransmitters and neurotransmitter transporter proteins originating from projections of dopaminergic neurons in substantia nigra pars compacta, serotonergic neurons in dorsal raphé nuclei, noradrenergic neurons in locus coeruleus, and cholinergic neurons in nucleus basalis of meynert. |
2015-10-19 |
2023-08-13 |
Not clear |
| Terina N Martinez, J Timothy Greenamyr. Toxin models of mitochondrial dysfunction in Parkinson's disease. Antioxidants & redox signaling. vol 16. issue 9. 2012-07-09. PMID:21554057. |
parkinson's disease (pd) is a neurodegenerative disorder characterized, in part, by the progressive and selective loss of dopaminergic neuron cell bodies within the substantia nigra pars compacta (snpc) and the associated deficiency of the neurotransmitter dopamine (da) in the striatum, which gives rise to the typical motor symptoms of pd. |
2012-07-09 |
2023-08-12 |
Not clear |
| Lichuan Yang, M Flint Bea. Determination of neurotransmitter levels in models of Parkinson's disease by HPLC-ECD. Methods in molecular biology (Clifton, N.J.). vol 793. 2011-12-30. PMID:21913116. |
the decrease in dopamine (da) neurotransmitter levels in the striatum and substantia nigra pars compacta is a neurochemistry hallmark of pd. |
2011-12-30 |
2023-08-12 |
drosophila_melanogaster |
| Li Rebekah Feng, Kathleen A Maguire-Zeis. Gene therapy in Parkinson's disease: rationale and current status. CNS drugs. vol 24. issue 3. 2010-05-04. PMID:20155994. |
parkinson's disease is the second most common age-related neurodegenerative disorder, typified by the progressive loss of substantia nigra pars compacta dopamine neurons and the consequent decrease in the neurotransmitter dopamine. |
2010-05-04 |
2023-08-12 |
Not clear |
| Hansruedi Büele. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease. Experimental neurology. vol 218. issue 2. 2009-09-04. PMID:19303005. |
parkinson's disease (pd), the most frequent movement disorder, is caused by the progressive loss of the dopamine neurons within the substantia nigra pars compacta (snc) and the associated deficiency of the neurotransmitter dopamine in the striatum. |
2009-09-04 |
2023-08-12 |
Not clear |
| Susan H Fox, Jonathan M Brotchie, Anthony E Lan. Non-dopaminergic treatments in development for Parkinson's disease. The Lancet. Neurology. vol 7. issue 10. 2008-12-18. PMID:18848312. |
clinical and pathological studies have shown that the disease extends beyond the substantia nigra pars compacta and involves various non-dopaminergic neurotransmitter systems that mediate both motor and non-motor symptoms that characterise pd. |
2008-12-18 |
2023-08-12 |
Not clear |
| T Nagatsu, M Sawad. Inflammatory process in Parkinson's disease: role for cytokines. Current pharmaceutical design. vol 11. issue 8. 2005-04-06. PMID:15777250. |
parkinson's disease (pd) is a movement disorder caused by degeneration of the nigrostriatal dopamine (da) neurons in the substantia nigra pars compacta and the resultant deficiency in the neurotransmitter da at the nerve terminals in the striatum. |
2005-04-06 |
2023-08-12 |
Not clear |
| Tomás González-Hernández, Pedro Barroso-Chinea, Manuel Rodrígue. Response of the GABAergic and dopaminergic mesostriatal projections to the lesion of the contralateral dopaminergic mesostriatal pathway in the rat. Movement disorders : official journal of the Movement Disorder Society. vol 19. issue 9. 2004-12-21. PMID:15372592. |
although dopamine is the main neurotransmitter in the mesostriatal system, recent studies indicate the existence of two nigrostriatal gabaergic projections: one arising from neurons immunoreactive for gaba, glutamic acid decarboxylase (gad67), and parvalbumin (pv) lying in the substantia nigra pars reticulata (nigrostriatal gaba cells) and the other arising from a subpopulation of dopaminergic neurons lying in the substantia nigra pars compacta and ventral tegmental area, which under normal conditions, contains mrna for gad65 (one of the two isoforms of glutamic acid decarboxylase), but which is not immunoreactive for gaba and gad65 (nigrostriatal dopaminergic [da]/gaba cells). |
2004-12-21 |
2023-08-12 |
rat |
| Andreas Hermann, Manfred Gerlach, Johannes Schwarz, Alexander Storc. Neurorestoration in Parkinson's disease by cell replacement and endogenous regeneration. Expert opinion on biological therapy. vol 4. issue 2. 2004-07-21. PMID:14998773. |
parkinson's disease (pd) is characterised by a continuous and selective loss of dopaminergic neurons in the substantia nigra pars compacta with a subsequent reduction of the neurotransmitter dopamine. |
2004-07-21 |
2023-08-12 |
Not clear |